Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins for the treatment of diabetes mellitus. Also described are specific covalent inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the described compounds. Methods of using the menin-MLL covalent inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes mellitus.
Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific irreversible inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
C07D 241/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Disclosed herein are macrocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia, lung cancer, colorectal cancer, pancreatic cancer, and other diseases or conditions dependent on KRas interaction.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/504 - PyridazinesHydrogenated pyridazines forming part of bridged ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
4.
CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE AS IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I),
Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I),
Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I),
including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
Disclosed herein are heterocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia, lung cancer, colorectal cancer, pancreatic cancer, and other diseases or conditions dependent on KRas interaction.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific covalent inhibitors of a menin or menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds described herein. Methods of using the menin or menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin or menin-MLL interaction.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
7.
N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOF
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
8.
CRYSTALLINE FORMS OF AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION
Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
A61P 35/02 - Antineoplastic agents specific for leukemia
9.
Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide]
Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I),
including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 35/02 - Antineoplastic agents specific for leukemia
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
C07D 241/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
11.
CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(L-OXO-2-PROPEN-L-YL)AMINO]-L-PIPERIDINYL]METHYL]-2- PYRIDINECARBOXAMIDE AS A COVALENTINHIBITOR OF MENIN-MLL INTERACTION
Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I), including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
A61P 35/02 - Antineoplastic agents specific for leukemia
12.
CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6- YL]PHENYL]-4-[[3(R)-[(L-OXO-2-PROPEN-L-YL)AMINO]-L-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE AS A COVALENT INHIBITOR OF MENIN-MLL INTERACTION
Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I), including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Methods and compositions using novel menin-MLL inhibitors enhancing proliferation of pancreatic beta cells to increase the efficacy of cell-based therapeutics are disclosed. Also provided are cell-based therapy methods and compositions.
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific covalent inhibitors of a menin or menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds described herein. Methods of using the menin or menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin or menin-MLL interaction.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Disclosed herein are combinations comprising an inhibitor of FLT3 and an inhibitor of menin. Also described are combinations of specific irreversible inhibitors of FLT3 and irreversible inhibitors of menin. Also described are methods of using the combinations for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
Disclosed herein are heterocyclic compounds, for example, according to the following formula and analogs thereof:
that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 241/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
C07D 241/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 241/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Disclosed herein are macrocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia, lung cancer, colorectal cancer, pancreatic cancer, and other diseases or conditions dependent on KRas interaction.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/504 - PyridazinesHydrogenated pyridazines forming part of bridged ring systems
25.
Covalent inhibitors of menin-MLL interaction for diabetes mellitus
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins for the treatment of diabetes mellitus. Also described are specific covalent inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the described compounds. Methods of using the menin-MLL covalent inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes mellitus.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
26.
Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction
Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (I)
including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include compound (I), as well as methods of using compound (I), alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Disclosed herein are heterocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia, lung cancer, colorectal cancer, pancreatic cancer, and other diseases or conditions dependent on KRas interaction.
C07D 473/04 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
28.
PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3
Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific irreversible inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
C07D 241/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific irreversible inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
C07D 241/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
30.
CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCER
The present invention relates to crystalline forms of N-[4-[4- (4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4- [[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2- pyridinecarboxamide (formula (I)). The compound of formula (I) is an irreversible menin-MLL inhibitor for use in the treatment of e.g. cancer, including e.g. lymphoma and leukemia, and autoimmune diseases. The present invention discloses the characterisation of crystalline forms by e.g. XRPD, FTIR, DSC and TGA as well as pharmacological data.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
31.
CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCE
The present invention relates to crystalline forms of N-[4-[4- (4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4- [[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2- pyridinecarboxamide (formula (I)). The compound of formula (I) is an irreversible menin-MLL inhibitor for use in the treatment of e.g. cancer, including e.g. lymphoma and leukemia, and autoimmune diseases. The present invention discloses the characterisation of crystalline forms by e.g. XRPD, FTIR, DSC and TGA as well as pharmacological data.
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins for the treatment of diabetes mellitus. Also described are specific covalent inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the described compounds. Methods of using the menin-MLL covalent inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes mellitus.
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins for the treatment of diabetes mellitus. Also described are specific covalent inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the described compounds. Methods of using the menin-MLL covalent inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes mellitus.
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Disclosed herein are heterocyclic compounds according to formula (I) having the structure
that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-HLL interaction. Also disclosed are pharmaceutical compositions that include compounds according to formula (I). Methods of using the menin-HLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical information; Providing information in the field of the diagnosis and treatment of cancer and metabolic diseases via a website; Providing medical information via a website
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Chemotherapeutics; Adjuvants for use with vaccines for medical purposes; Anti-cancer preparations; Anti-sarcoma preparations; Pharmaceutical preparations, namely, antagonists for activating cellular function; Chemical preparations for the treatment of cancer and metabolic diseases, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Cytostatics for the inhibition and suppression of cellular growth and multiplication; Contrast agent for ultrasound diagnostic imaging; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, diabetes; Diagnostic reagents and agents for medical diagnostic use; Medical diagnostic assay kits comprised of medical diagnostic reagents and assays for detecting cancer; Reagents for use in testing proteins for medical diagnostic purposes; Medicines for human use for the treatment of cancer and metabolic diseases, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Medicines for human use for the treatment of cancer and infectious diseases, namely, respiratory infections, eye infections; Pharmaceutical preparations for the treatment of damaged skin and tissue namely bee stings, sunburn, rashes, sores, corns, calluses and acne; Pharmaceutical preparations and substances for the treatment of respiratory infections, eye infections, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, and hormonal related diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral diseases and disorders, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), metabolic diseases and disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia, endocrine diseases and disorders, namely, glucagonoma, genitourinary diseases and disorders, namely, urological diseases, infertility, sexually transmitted diseases, and inflammatory pelvic diseases, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, and cerebral palsy, dermatological diseases and disorders, namely, parasitic skin infections, psoriasis, and eczema, psychiatric diseases and disorders, namely, anxiety disorders, schizophrenia, and bipolar disorders, and immune system diseases and disorders, namely, autoimmune diseases and disorders; Pharmaceutical preparations for treating chemical imbalances namely, depression and anxiety; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the prevention of cancer and metabolic diseases namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Pharmaceutical preparations, namely, elixirs for the treatment of cancer and metabolic diseases namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Tumor suppressing agents; Medicinal infusions for treating cancer and metabolic diseases namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets that facilitate the delivery of pharmaceutical preparations (1) Research in the medical biotechnology field; Development of new technology for others in the field of cancer and metabolic diseases namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Development of pharmaceutical preparations and medicines; Medical and scientific research in the field of cancer treatment and diagnosis; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Providing information on the subject of scientific research in the field of biochemistry and medical biotechnology; Providing medical research and scientific research information in the field of oncology via the Internet; Providing medical testing services and information in the field of cancer research and disease classification; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development in the pharmaceutical and medical biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases namely, Parkinson's Disease, Alzheimer's Disease, and Osteoarthritis and cancer; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of cancer and metabolic diseases namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Testing of pharmaceuticals; Medical research services; Pharmaceutical research services; Research and development of vaccines and medicines
(2) Providing health and medical information in the field of oncology via a website; Providing information on the topic of diagnosis and treatment of cancer and metabolic disease namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia via a website
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemotherapeutics; adjuvants for medical purposes; anti-cancer preparations; anti-sarcoma preparations; cellular function activating agents for medical purposes; chemical preparations for pharmaceutical or medical purposes, namely, for cancer and metabolic diseases; cytostatics for pharmaceutical purposes; diagnostic preparations for medical purposes; medical preparations for the treatment of cancer and metabolic diseases; medicinal preparations for the treatment of infectious diseases and for use in oncology; medicinal preparations for cancer and metabolic diseases; pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for treating chemical imbalances; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the prevention of cancer and metabolic diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of cancer and metabolic diseases; pharmaceutical preparations for the treatment and prevention of cancer and metabolic diseases; pharmaceutical preparations for cancer and metabolic diseases; pharmaceutical preparations, namely, elixirs for the treatment of cancer and metabolic diseases; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; therapeutic pharmaceutical products for the treatment of cancer and metabolic diseases; tumor suppressing agents; medicinal infusions for treating cancer and metabolic diseases; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents. Biotechnology research; development of new technology for others in the field of cancer and metabolic diseases; development of pharmaceutical preparations and medicines; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical drug development services; pharmaceutical products development; pharmaceutical research and development; providing information on the subject of scientific research in the field of biochemistry and biotechnology; providing medical research and scientific research information in the field of oncology via the internet; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; research and development of pharmaceuticals for the treatment of age-related diseases and cancer; scientific research for medical purposes in the area of cancerous diseases; scientific research for medical purposes in the field of cancer and metabolic diseases; testing of pharmaceuticals; medical research services; pharmaceutical research services; research and development of vaccines and medicines. Providing a web site with medical information; providing a website with information in the field of the diagnosis and treatment of cancer and metabolic diseases; providing medical testing services and information in the field of cancer research and disease classification.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Chemotherapeutics; Adjuvants for use with vaccines for medical purposes; Anti-cancer preparations; Anti-sarcoma preparations; Pharmaceutical preparations, namely, antagonists for activating cellular function; Chemical preparations for the treatment of cancer and metabolic diseases, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Cytostatics for the inhibition and suppression of cellular growth and multiplication; Contrast agent for ultrasound diagnostic imaging; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, diabetes; Diagnostic reagents and agents for medical diagnostic use; Medical diagnostic assay kits comprised of medical diagnostic reagents and assays for detecting cancer; Reagents for use in testing proteins for medical diagnostic purposes; Medicines for human use for the treatment of cancer and metabolic diseases, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Medicines for human use for the treatment of cancer and infectious diseases, namely, respiratory infections, eye infections; Pharmaceutical preparations for the treatment of damaged skin and tissue namely bee stings, sunburn, rashes, sores, corns, calluses and acne; Pharmaceutical preparations and substances for the treatment of respiratory infections, eye infections, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, and hormonal related diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral diseases and disorders, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), metabolic diseases and disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia, endocrine diseases and disorders, namely, glucagonoma, genitourinary diseases and disorders, namely, urological diseases, infertility, sexually transmitted diseases, and inflammatory pelvic diseases, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, and cerebral palsy, dermatological diseases and disorders, namely, parasitic skin infections, psoriasis, and eczema, psychiatric diseases and disorders, namely, anxiety disorders, schizophrenia, and bipolar disorders, and immune system diseases and disorders, namely, autoimmune diseases and disorders; Pharmaceutical preparations for treating chemical imbalances namely, depression and anxiety; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the prevention of cancer and metabolic diseases namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Pharmaceutical preparations, namely, elixirs for the treatment of cancer and metabolic diseases namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Tumor suppressing agents; Medicinal infusions for treating cancer and metabolic diseases namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets that facilitate the delivery of pharmaceutical preparations (1) Research in the medical biotechnology field; Development of new technology for others in the field of cancer and metabolic diseases namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Development of pharmaceutical preparations and medicines; Medical and scientific research in the field of cancer treatment and diagnosis; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Providing information on the subject of scientific research in the field of biochemistry and medical biotechnology; Providing medical research and scientific research information in the field of oncology via the Internet; Providing medical testing services and information in the field of cancer research and disease classification; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development in the pharmaceutical and medical biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases namely, Parkinson's Disease, Alzheimer's Disease, and Osteoarthritis and cancer; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of cancer and metabolic diseases namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia; Testing of pharmaceuticals; Medical research services; Pharmaceutical research services; Research and development of vaccines and medicines
(2) Providing health and medical information in the field of oncology via a website; Providing information on the topic of diagnosis and treatment of cancer and metabolic disease namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, gout, arthritis and anemia via a website
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemotherapeutics; adjuvants for medical purposes; anti-cancer preparations; anti-sarcoma preparations; cellular function activating agents for medical purposes; chemical preparations for pharmaceutical or medical purposes, namely, for cancer and metabolic diseases; cytostatics for pharmaceutical purposes; diagnostic preparations for medical purposes; medical preparations for the treatment of cancer and metabolic diseases; medicinal preparations for the treatment of infectious diseases and for use in oncology; medicinal preparations for cancer and metabolic diseases; pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for treating chemical imbalances; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the prevention of cancer and metabolic diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of cancer and metabolic diseases; pharmaceutical preparations for the treatment and prevention of cancer and metabolic diseases; pharmaceutical preparations for cancer and metabolic diseases; pharmaceutical preparations, namely, elixirs for the treatment of cancer and metabolic diseases; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; therapeutic pharmaceutical products for the treatment of cancer and metabolic diseases; tumor suppressing agents; medicinal infusions for treating cancer and metabolic diseases; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents. Biotechnology research; development of new technology for others in the field of cancer and metabolic diseases; development of pharmaceutical preparations and medicines; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical drug development services; pharmaceutical products development; pharmaceutical research and development; providing information on the subject of scientific research in the field of biochemistry and biotechnology; providing medical research and scientific research information in the field of oncology via the internet; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; research and development of pharmaceuticals for the treatment of age-related diseases and cancer; scientific research for medical purposes in the area of cancerous diseases; scientific research for medical purposes in the field of cancer and metabolic diseases; testing of pharmaceuticals; medical research services; pharmaceutical research services; research and development of vaccines and medicines. Providing a web site with medical information; providing a website with information in the field of the diagnosis and treatment of cancer and metabolic diseases; providing medical testing services and information in the field of cancer research and disease classification.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Adjuvants for medical purposes; Anti-cancer preparations; Anti-sarcoma preparations; Cellular function activating agents for medical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer and metabolic diseases; Chemotherapeutics; Cytostatics for pharmaceutical purposes; Diagnostic preparations for medical purposes; Medical preparations for the treatment of cancer and metabolic diseases; Medicinal infusions for treating cancer and metabolic diseases; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for cancer and metabolic diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment and prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of cancer and metabolic diseases; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for cancer and metabolic diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, elixirs for the treatment of cancer and metabolic diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer and metabolic diseases; Tumor suppressing agents Biotechnology research; Development of new technology for others in the field of cancer and metabolic diseases; Development of pharmaceutical preparations and medicines; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research services; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing medical research and scientific research information in the field of oncology via the Internet; Providing medical testing services and information in the field of cancer research and disease classification; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of cancer and metabolic diseases; Testing of pharmaceuticals
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Adjuvants for medical purposes; Anti-cancer preparations; Anti-sarcoma preparations; Cellular function activating agents for medical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer and metabolic diseases; Chemotherapeutics; Cytostatics for pharmaceutical purposes; Diagnostic preparations for medical purposes; Medical preparations for the treatment of cancer and metabolic diseases; Medicinal infusions for treating cancer and metabolic diseases; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for cancer and metabolic diseases; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment and prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of cancer and metabolic diseases; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for cancer and metabolic diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, elixirs for the treatment of cancer and metabolic diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer and metabolic diseases; Tumor suppressing agents Biotechnology research; Development of new technology for others in the field of cancer and metabolic diseases; Development of pharmaceutical preparations and medicines; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research services; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing medical research and scientific research information in the field of oncology via the Internet; Providing medical testing services and information in the field of cancer research and disease classification; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of cancer and metabolic diseases; Testing of pharmaceuticals Providing a web site featuring medical information; Providing a website featuring information in the field of the diagnosis and treatment of cancer and metabolic diseases
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing a web site featuring medical information; Providing a website featuring information in the field of the diagnosis and treatment of cancer and metabolic diseases
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing a web site featuring medical information; Providing a website featuring information in the field of the diagnosis and treatment of cancer and metabolic diseases
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemotherapeutics; Adjuvants for medical purposes; Anti-cancer preparations; Anti-sarcoma preparations; Cellular function activating agents for medical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer and metabolic diseases; Cytostatics for pharmaceutical purposes; Diagnostic preparations for medical purposes; Medical preparations for the treatment of cancer and metabolic diseases; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for cancer and metabolic diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of cancer and metabolic diseases; Pharmaceutical preparations for the treatment and prevention of cancer and metabolic diseases; Pharmaceutical preparations for cancer and metabolic diseases; Pharmaceutical preparations, namely, elixirs for the treatment of cancer and metabolic diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer and metabolic diseases; Tumor suppressing agents; Medicinal infusions for treating cancer and metabolic diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents Biotechnology research; Development of new technology for others in the field of cancer and metabolic diseases; Development of pharmaceutical preparations and medicines; Medical and scientific research in the field of cancer treatment and diagnosis; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical research and scientific research information in the field of oncology via the Internet; Providing medical testing services and information in the field of cancer research and disease classification; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of cancer and metabolic diseases; Testing of pharmaceuticals; Medical research services; Pharmaceutical research services; Research and development of vaccines and medicines
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing information on the subject of scientific research in the field
of biochemistry and biotechnology; Providing medical research and
scientific research information in the field of oncology via the Internet;
Providing medical testing services and resulting information in the
field of cancer research and disease classification; Providing medical
and scientific research information in the field of pharmaceuticals and
clinical trials; Providing medical and scientific research information in
the fields of pharmaceuticals and genetics
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction;
or a pharmaceutically acceptable salt thereof.
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
